Francesc Bosch

23PUBLICATIONS
165CO-AUTHORS
Medical mycologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Apr 30, 2026
How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?

|Oct 20, 2025
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.

Martin Hutchings, Anna Sureda, Francesc Bosch

|Jun 06, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Jeff P Sharman, Talha Munir, Sebastian Grosicki

|Apr 24, 2025
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.

Birna Thorvaldsdottir, Larry Mansouri, Lesley-Ann Sutton

|Nov 21, 2024
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas.

Elise A Chong, Elicia Penuel, Ellen B Napier

|Jul 29, 2024
Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion.

Maria Julia Montoro, Laura Palomo, Claudia Haferlach

Pageof 4

Frequent Collaborators

4 joint publications

David Valcarcel

3 joint publications

Pere Barba

3 joint publications

Lihua E Budde

3 joint publications

Ian W Flinn